1. Home
  2. Stocks
  3. Neulandlab Share Price

Neuland Laboratories Share Price

Pharmaceuticals Large Cap

₹15,858.20 +1129.4 (7.67%)

05 Nov, 2024 17:20

SIP TrendupStart SIP in NEULANDLAB

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹14,729
  • High
  • ₹15,939
  • 52 Week Low
  • ₹3,930
  • 52 Week High
  • ₹16,525
  • Open Price₹14,729
  • Previous Close₹14,729
  • Volume49,090

Investment Returns

  • Over 1 Month + 31.31%
  • Over 3 Month + 43.15%
  • Over 6 Month + 109.82%
  • Over 1 Year + 310.14%
SIP Lightning

Smart Investing Starts Here Start SIP with Neuland Laboratories for Steady Growth!

Neuland Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 60.5
  • PEG Ratio
  • 1.1
  • Market Cap Cr
  • 20,346
  • P/B Ratio
  • 16
  • Average True Range
  • 787.33
  • EPS
  • 233.7
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 433.61
  • RSI
  • 60.45
  • MFI
  • 49.63

Neuland Laboratories Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations439.60385.01392.83417.75362.99
Total Income From Operations439.60385.01392.83417.75362.99
P/L Before Interest, Excpt. Items & Tax112.3595.69107.52125.8485.72
P/L Before Exceptional Items & Tax109.6892.08103.78121.4083.50
P/L After Tax from Ordinary Activities98.3467.6180.7089.0662.22
Net Profit/Loss For the Period98.3467.6180.7089.0662.22
IndicatorMar 24Mar 23
Revenue From Operations [Gross]1,515.661,160.90
Revenue From Operations [Net]1,515.661,160.90
Total Operating Revenues1,558.581,191.20
Total Revenue1,571.121,200.95
Total Expenses1,170.36985.73
Profit/Loss Before Tax400.77215.21
Profit/Loss For The Period299.60163.12
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity260.06238.53
Net Cash Used In Investing Activity-149.67-61.50
Net Cash Used in Finance Activity-69.28-135.80
Net Inc/Dec In Cash And Equivalent41.1141.24
Cash And Equivalent End Of Year86.0744.96
IndicatorMar 24Mar 23
Total Share Capital12.9012.90
Total Non-Current Liabilities120.59145.22
Total Current Liabilities433.80445.75
Total Capital And Liabilities1,830.931,579.34
Total Non-Current Assets911.46819.00
Total Current Assets919.47760.34
Total Assets1,830.931,579.34
Indicator20242023
EBIT Margin (%)26.6119.16
Return On Capital Employed (%)29.6820.13
Return On Equity (%)23.4816.51
Long Term Debt To Equity (%)3.527.51
Book Value/Share (INR)988.88765.49
IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations439.60385.01392.83417.75362.99
Total Income From Operations439.60385.01392.83417.75362.99
P/L Before Interest, Excpt. Items & Tax111.8995.81108.22126.0385.37
P/L Before Exceptional Items & Tax109.2292.20104.48121.5983.16
P/L After Tax from Ordinary Activities97.8767.5681.3989.2561.88
Net Profit/Loss For the Period97.8767.5681.3989.2561.88
IndicatorMar 24Mar 23
Revenue From Operations [Gross]1,515.661,160.90
Revenue From Operations [Net]1,515.661,160.90
Total Operating Revenues1,558.581,191.20
Total Revenue1,571.121,200.95
Total Expenses1,169.69985.20
Profit/Loss Before Tax401.44215.75
Profit/Loss For The Period300.08163.52
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity261.18237.21
Net Cash Used In Investing Activity-149.69-61.50
Net Cash Used in Finance Activity-69.28-135.80
Net Inc/Dec In Cash And Equivalent42.1640.32
Cash And Equivalent End Of Year87.5845.42
IndicatorMar 24Mar 23
Total Share Capital12.9012.90
Total Non-Current Liabilities122.17146.71
Total Current Liabilities427.68438.96
Total Capital And Liabilities1,832.561,579.76
Total Non-Current Assets911.48818.87
Total Current Assets921.08760.89
Total Assets1,832.561,579.76
Indicator20242023
EBIT Margin (%)26.6519.20
Return On Capital Employed (%)29.5720.05
Return On Equity (%)23.4016.46
Long Term Debt To Equity (%)3.507.47
Book Value/Share (INR)993.66769.94

Neuland Laboratories Technicals

EMA & SMA

Current Price
₹15,858.20
+ 1129.4 (7.67%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹13,904.93
  • 50 Day
  • ₹12,934.41
  • 100 Day
  • ₹11,433.14
  • 200 Day
  • ₹9,415.34

Resistance and Support

14788.77 Pivot Speed
  • R3 15,728.53
  • R2 15,435.27
  • R1 15,082.03
  • S1 14,435.53
  • S2 14,142.27
  • S3 13,789.03

Is Neuland Laboratories Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Neuland Laboratories is a leading pharmaceutical company specializing in the manufacturing of active pharmaceutical ingredients (APIs) and custom manufacturing solutions. It serves global pharmaceutical companies with high-quality APIs for critical therapeutic areas, including cardiovascular and central nervous system. Neuland Laboratories has an operating revenue of Rs. 1,635.19 Cr. on a trailing 12-month basis. An annual revenue growth of 31% is outstanding, Pre-tax margin of 26% is great, ROE of 23% is exceptional. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 12% and 68% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 92 which is a GREAT score indicating consistency in earnings, a RS Rating of 94 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of A is the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Neuland Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-06 Quarterly Results
2024-08-01 Quarterly Results
2024-05-10 Audited Results & Final Dividend
2024-02-08 Quarterly Results
2023-11-07 Quarterly Results
Date Purpose Remarks
2022-07-15 FINAL Rs.5.00 per share(50%)Final Dividend

Neuland Laboratories F&O

Neuland Laboratories Shareholding Pattern

32.64%
4.04%
0.4%
26.46%
26.5%
9.96%
  • NSE Symbol
  • NEULANDLAB
  • BSE Symbol
  • 524558
  • ISIN
  • INE794A01010

Neuland Laboratories FAQs

Neuland Laboratories share price is ₹15,858 As on 05 November, 2024 | 17:06

The Market Cap of Neuland Laboratories is ₹20345.9 Cr As on 05 November, 2024 | 17:06

The P/E ratio of Neuland Laboratories is 60.5 As on 05 November, 2024 | 17:06

The PB ratio of Neuland Laboratories is 16 As on 05 November, 2024 | 17:06

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.